Bioplus announced on the 28th that its new factory ‘Bio Complex’ in Eumseong, Chungcheongbuk-do, in which it invested approximately 150 billion won, has been completed with approval for use. This new factory is expected to significantly expand the production capacity of biopharmaceuticals such as hyaluronic acid (HA) fillers, obesity and diabetes treatments, and botulinum toxin, thereby strengthening its competitiveness in the global market.
The 'Bio Complex' is a five-story facility with a total area of approximately 49,134 m2, and has an annual maximum production capacity of 40 million hyaluronic acid fillers, 40 million obesity and diabetes treatments, and 36 million botulinum toxins. It is the largest biopharmaceutical production facility in Korea, and the company explained that it is responding to domestic and international demand through it.
In particular, since the bio complex was built as a cGMP plant in compliance with the U.S. Food and Drug Administration (FDA) standards, it has favorable conditions for entering the U.S. market through future FDA approval. In addition to existing suppliers, the company is actively pursuing entry into the U.S. market, expecting that this will allow it to increase sales and strengthen its competitiveness in the global market.
A Bioplus official said, “With the completion of this new plant, we have established a fully automated line for the entire process, which has enabled us to reduce costs and secure price competitiveness.” He added that they plan to add a production line for the main raw material, pre-filled syringes, to vertically integrate the company’s business to ensure a stable supply of raw materials and quality, while also strengthening price competitiveness.
- See more related articles
You must be logged in to post a comment.